Bicara Therapeutics (Ticker: BCAX) is a clinical-stage biopharmaceutical company developing ficerafusp alfa, a bifunctional antibody aimed at treating head and neck squamous cell cancer. Incorporated in Delaware, the company is currently conducting a Phase 1/1b clinical trial in the U.S. for this drug candidate and plans to initiate a Phase 2/3 trial in late 2024 or early 2025.

Bicara Therapeutics will list on September 13, 2024, on NASDAQ. The firm is offering 11.77 million shares at a price range of $16.00 to $18.00 per share to raise approximately $200 million. The expected market capitalization at offer is $782.44 million. The offering is managed by Morgan Stanley, TD Cowen, Cantor, and Stifel.